BILL 8
Prescription Monitoring Act
Her Majesty, by and with the advice and
consent of the Legislative Assembly of New Brunswick, enacts as follows:
Definitions
1 The
following definitions apply in this Act.
“advisory committee” means
the Prescription Monitoring Program Advisory Committee established
under section 9. (comité
consultatif)
“Director” means the Director
of the Prescription Monitoring Program appointed under section 5. (directeur)
“licensed pharmacist” means
an individual who is registered as a pharmacist with the New Brunswick
Pharmaceutical Society and who holds a licence issued under section
31 of the Pharmacy Act. (pharmacien
titulaire de permis)
“licensing authority” means
the following bodies with statutory responsibility for the discipline
of health care providers or to regulate the quality or standards of
professional services provided by health care providers: (organisme
chargé de la délivrance des permis)
(a) the College of Physicians
and Surgeons of New Brunswick;
(b) the Dental Society
of New Brunswick;
(c) the New Brunswick
Pharmaceutical Society; and
(d) any other body designated
by regulation.
“member”, in relation to a
licensing authority, means a person who is registered with a licensing
authority and who holds a licence issued by that licensing authority. (membre)
“Minister” means the Minister
of Health. (ministre)
“monitored drug” means a drug
that is in a class of drugs designated by the regulations. (médicament
contrôlé)
“participant” means a prescriber
or licensed pharmacist registered in the program under section 6. (participant)
“patient monitoring agreement”
means a written agreement between a participant and a patient where
the patient agrees to comply with the terms and conditions of the
agreement with respect to any monitored drug. (entente
de surveillance du patient)
“personal health information”
means personal health information as defined in the Personal Health Information Privacy and
Access Act. (renseignements personnels sur la santé)
“pharmacy” means a pharmacy
with respect to which a valid certificate of accreditation has been
issued under the Pharmacy Act,
other than a pharmacy designated in the regulations. (pharmacie)
“prescriber” means an individual
who is entitled under an Act of the Legislature, an Act of another
province or territory of Canada or an Act of the Parliament of Canada
to prescribe monitored drugs, except an individual who is entitled
under the Veterinarians Act to
prescribe monitored drugs or under any similar Act of another province
or territory of Canada or of the Parliament of Canada. (prescripteur)
“program” means the Prescription
Monitoring Program established under section 3. (programme)
“program information” includes
the information submitted by a pharmacy under section 10 and the information with respect to
a patient monitoring agreement that is filed with the Director under
this Act. (renseignements aux fins d’application
du programme)
Conflict
2 If
there is a conflict between a provision of this Act and a provision
of the Personal Health Information
Privacy and Access Act or any provision of an Act of the Legislature
with respect to the protection of personal health information, this
Act prevails.
Prescription monitoring program
3 There
is established a Prescription Monitoring Program.
Purposes of the program
4 The
program shall provide prescribers and licensed pharmacists the ability
to monitor the prescribing or dispensing of monitored drugs to individuals
or the use of monitored drugs by individuals through the use of a
real time information network for the following purposes:
(a) to
promote optimal prescribing and utilization of monitored drugs for
legitimate medical purposes;
(b) to
enable early identification of individuals at risk for addiction;
and
(c) to
reduce the misuse and abuse of monitored drugs.
Director
5(1)
The Minister shall appoint an employee of the Civil Service, as defined
in the Civil Service Act,
as Director of the Prescription Monitoring Program.
5(2)
The Director may designate persons to act on the Director’s
behalf.
5(3) The Director shall
(a) prepare
a list of classes of drugs that may be designated as monitored drugs,
(b) evaluate
patterns in the prescribing and dispensing of monitored drugs,
(c) report
program information to members and to licensing authorities,
(d) inform
the advisory committee with respect to information relating to the
program,
(e) evaluate
the effectiveness of the program,
(f) provide
public education on the program’s objectives and parameters,
and
(g) perform
or exercise any additional power or duty assigned by the Minister
or that is prescribed by regulation.
Registration in the program
6(1)
On application to the Director, the Director shall register in the
program a prescriber who prescribes monitored drugs or a licensed
pharmacist who dispenses monitored drugs.
6(2)
An application shall be made in the form and manner required by the
Director.
Information respecting the program
7 A
participant shall have access to program information and to other
information prescribed by regulation.
Information network
8(1)
The Minister shall establish and maintain a real time information
network to monitor the prescribing, dispensing or use of monitored
drugs.
8(2) Subject to this Act and the regulations,
the Minister may, with respect to the information network,
(a) establish
requirements for information that must be supplied to the network
and the format in which the information must be supplied and may make
those requirements known electronically to participants and pharmacies,
(b) establish
rules, procedures and guidelines respecting the use of the information
network, and
(c) establish
any other requirement, rule, procedure or guideline in order to ensure
the proper functioning of the information network.
8(3)
The Minister may delegate, in writing, any power or duty conferred
or imposed on the Minister under subsections (1) and (2) to any person.
8(4)
In a delegation under this section, the Minister shall
(a) establish
the manner in which the delegate is to exercise the delegated authority,
and
(b) impose
on the delegate any limitations, terms, conditions and requirements
that the Minister considers appropriate.
8(5)
The Minister may revoke, in whole or in part, a delegation under this
section.
8(6) A delegate under this section shall
exercise the delegated authority in the manner established in, and
in accordance with any limitations, terms, conditions and requirements
imposed in the delegation.
8(7)
A delegate under this section shall comply with the same requirements
concerning the protection, retention and secure destruction of personal
health information that the Minister is required to comply with under
the Personal Health Information Privacy
and Access Act.
8(8)
Subject to this Act and the regulations, no person other than a participant
or a pharmacy shall submit information to the information network.
8(9)
Subject to this Act and the regulations, the Minister shall determine
the persons who may have access to the information network.
Advisory committee
9(1)
There is established an advisory committee known as the Prescription
Monitoring Program Advisory Committee consisting of the following
members:
(a) the
Director;
(b) one
individual appointed by the Minister for each licensing authority
nominated by each licensing authority;
(c) a
prescriber appointed by the Minister;
(d) a
licensed pharmacist appointed by the Minister;
(e) a
person employed in the Department of Health appointed by the Minister;
(f) one
individual appointed by the Minister who has never worked as a health
care provider as that term is defined in the Personal Health Information Privacy and
Access Act and has never been a member of a licensing authority;
(g) no
more than 2 individuals appointed by the Minister nominated by a person
delegated any power or duty under this Act; and
(h) no
more than 2 other individuals appointed by the Minister.
9(2)
The advisory committee shall make recommendations and advise the Minister
on
(a) what
classes of drugs to be considered for designation as monitored drugs,
(b) policy
and other matters related to the program,
(c) possible
amendments to this Act or the regulations to further the purposes
of the program,
(d) issues
arising from the collection and reporting of information under the
program, and
(e) any
other matter established by regulation.
Requirements of pharmacies
10(1)
Until the commencement of subsection (2), a pharmacy may submit to
the Minister personal health information with respect to an individual
to whom a monitored drug is dispensed.
10(2)
When dispensing a monitored drug to an individual, a pharmacy shall
submit to the information network, in the form and in the manner required
by the Director, the following information:
(a) the
Medicare number of the individual to whom a monitored drug was prescribed
or any other identifier prescribed by regulation;
(b) the
first name, surname, date of birth, gender and address of the individual
to whom the monitored drug was prescribed;
(c) the
first name, surname, licence number and address of the prescriber
who prescribed the monitored drug;
(d) the
name, address and telephone and facsimilie number of the pharmacy
dispensing the monitored drug;
(e) the
first name, surname and licence number of the licensed pharmacist
who dispensed the monitored drug;
(f) the
name, strength and quantity of the monitored drug;
(g) the
identity of the manufacturer of the monitored drug;
(h) the
date on which the monitored drug is dispensed; and
(i) any
other information prescribed by regulation.
Duties of licensing authorities
11 A
licensing authority that revokes, suspends or otherwise alters the
privileges of a member or pharmacy with respect to the prescribing
or dispensing of a monitored drug shall notify the Director in writing
within 2 days after the date the licence was revoked, suspended or
altered, as the case may be.
Patient monitoring agreement
12 A
participant may, with the consent of his or her patient, file with
the Director the information prescribed by regulation with respect
to a patient monitoring agreement.
Administration
13 The
Minister is responsible for the administration of this Act and may
designate one or more persons to act on the Minister’s behalf.
Agreements
14 The
Minister may enter into agreements with any institution, agency, person
or other Minister of the Crown for the administration of the program
and the institution, agency or person shall comply with the agreement.
Actions done in good faith
15 No
action or other proceeding lies against the Province of New Brunswick,
the Minister, the Director, the advisory committee, a licensing authority,
a participant, a pharmacy, a delegate under subsection 8(3), a party to an agreement under section 14 or any other person acting under the
authority of this Act for any act done in good faith in the execution
or intended execution of any duty or power under this Act or for any
alleged neglect or default in the execution in good faith of any such
duty or power.
Prohibition
16 No
person shall use or disclose to another person any program information
or any other information recorded in the information network except
as is necessary to carry out his or her powers or duties under this
Act or the regulations.
Offences
17(1)
A person who violates or fails to comply with subsection 8(8) commits an offence punishable under
Part II of the Provincial Offences
Procedure Act as a category F offence.
17(2)
A pharmacy that violates or fails to comply with subsection 10(2) commits an offence punishable under
Part II of the Provincial Offences
Procedure Act as a category C offence.
17(3)
A licensing authority that violates or fails to comply with section 11 commits an offence punishable under
Part II of the Provincial Offences
Procedure Act as a category C offence.
17(4)
An institution, agency or person who has entered into an agreement
under section 14 and who violates
or fails to comply with the agreement commits an offence punishable
under Part II of the Provincial Offences
Procedure Act as a category F offence.
17(5)
A person who violates or fails to comply with section 16 commits an offence punishable under
Part II of the Provincial Offences
Procedure Act as a category F offence.
17(6)
Subject to subsection (7), a person who violates or fails to comply
with a provision of the regulations commits an offence punishable
under Part II of the Provincial Offences
Procedure Act as a category C offence.
17(7)
A person who violates or fails to comply with a provision of the regulations
in respect of which a category has been prescribed under paragraph 18(o)
commits an offence of the category prescribed by regulation.
17(8)
If an offence under this Act or the regulations continues for more
than one day,
(a) the
minimum fine that may be imposed is the minimum fine set by the Provincial Offences Procedure Act multiplied
by the number of days during which the offence continues, and
(b) the
maximum fine that may be imposed is the maximum fine set by the Provincial Offences Procedure Act multiplied
by the number of days during which the offence continues.
17(9)
No prosecution for an offence under this Act or the regulations shall
be commenced after 2 years from the date of the discovery of the alleged
offence.
Regulations
18 The
Lieutenant-Governor in Council may make regulations
(a) prescribing
a body for the purposes of the definition “licensing authority”
in section 1;
(b) designating
a class of drugs for the purposes of the definition “monitored
drug” in section 1;
(c)
designating a pharmacy for the purposes of the definition “pharmacy”
in section 1;
(d) incorporating
by reference, in whole or in part, a list of classes of drugs for
the purposes of designating a class of drugs as monitored drugs, as
it reads on a fixed day or as it is amended from time to time;
(e) prescribing
the powers or duties of the Director under paragraph 5(3)(g);
(f) prescribing
other information in relation to the program to which a participant
shall have access;
(g) respecting
the information network, including, but not limited to, the persons
who may have access to the information network, the information to
be submitted to or recorded by the information network, the provision
of threshold alerts, patient exception status alerts and the triggering
of those alerts;
(h) respecting
the appointment of the advisory committee, including the size, composition,
the term of office, the procedures and the quorum of the advisory
committee;
(i) respecting
the designation of the chair and vice-chair of the advisory committee;
(j) respecting
conflicts of interest pertaining to members of the advisory committee,
including the circumstances that constitute a conflict of interest,
the disclosure of a conflict of interest and the manner in which a
conflict of interest is to be dealt with;
(k) fixing
the remuneration of members of the advisory committee and the expenses
to be paid to members of advisory committees while attending meetings
and otherwise carrying out their prescribed duties;
(l) establishing
any other matter for the purposes of paragraph 9(2)(e);
(m) prescribing
the identifier referred to in paragraph 10(2)(a) of an individual to whom a monitored
drug is prescribed;
(n) prescribing
any other information under paragraph 10(2)(i) to be submitted to the information
network by a pharmacy;
(o) prescribing
the information with respect to a patient monitoring agreement to
be filed with the Director for the purposes of section 12;
(p) prescribing,
in respect of offences under the regulations, categories of offences
for the purposes of Part II of the Provincial
Offences Procedure Act;
(q) respecting
any other matter or thing necessary or advisable to carry out the
intent of this Act.
Review of this Act
19 Within
4 years after the commencement of this Act, the Minister shall undertake
a comprehensive review of the operation of this Act and shall, within
one year after the review is undertaken or within such further time
as the Legislative Assembly may allow, submit a report on the review
to the Legislative Assembly.
COMMENCEMENT
Commencement
20 This Act or any provision of it comes into
force on a day or days to be fixed by proclamation.